Japan’s Oncolys, Taiwan’s Medigen Team For Telomelysin Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
Japan's Oncolys BioPharma and the Taiwanese biotech Medigen Biotechnology have formed a partnership to develop Oncolys's Telomelysin cancer drug for Asian markets. The drug is a genetically modified form of the adenovirus that thrives only in cancer cells. Telomelysin is undergoing U.S. clinical trials as a treatment for tongue and esophageal cancers. Under the partnership, Medigen is to conduct Taiwan tests on the drug for treating liver cancer. (Click here for more - a subscription may be required